Indoco Remedies Limited, a Rs.980 crore plus pharma major from Mumbai, has received UK MHRA regulatory approval for its solid dosages manufacturing facility in Goa (Plant I). This approval is the outcome of the inspection conducted in December 2016. The plant contributes to 40 per cent of compay's international business.
"The approval from UK MHRA for our Goa solid dosages facility will provide further impetus to our existing efforts in the European region”. This is the sixth time the Goa Plant I has successfully faced UK MHRA inspection and received approval from time to time since 2003, thereby confirming Indoco’s consistent adherence to international standards and good manufacturing practices, said Aditi Panandikar, managing director, Indoco Remedies.
Indoco Remedies is a fully integrated, research-oriented pharma company with presence in 55 countries. The company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D centre and a CRO facility. The facilities have been approved by US FDA, UK MHRA, TGA-Australia, MCC-South Africa, etc.